Holen Sie sich die Stockscreener-App
9.20
2.75%
-0.26
Handel nachbörslich:
9.00
-0.20
-2.17%
Schlusskurs vom Vortag:
$9.46
Offen:
$9.51
24-Stunden-Volumen:
493.15K
Relative Volume:
0.62
Marktkapitalisierung:
$686.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.91%
1M Leistung:
-7.07%
6M Leistung:
-45.64%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.20
$10.02
1-Wochen-Bereich:
$8.48
$10.02
52-Wochen-Spanne:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-785-8308
Adresse
245 MAIN STREET, CAMBRIDGE
Vergleichen Sie BCAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
9.20 | 686.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks
Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals
# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com
Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World
Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN
Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock - Investing.com
Bicara Therapeutics Expands Boston Headquarters with New Lease - TipRanks
25,028 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Merus Raises $300m After ASCO Success - insights.citeline.com
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Cantor Fitzgerald maintains overweight rating on Bicara stock By Investing.com - Investing.com India
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target - TipRanks
Cantor Fitzgerald maintains overweight rating on Bicara stock - Investing.com
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock - Investing.com India
Stifel reiterates Buy rating on Bicara Therapeutics stock - Investing.com Australia
Stifel reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 - BioSpace
Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating - TipRanks
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara presents promising early-stage data in head and neck cancers - The Business Journals
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - The Manila Times
Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer - Nasdaq
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus ... - Enidnews.com
Bicara Therapeutics Demonstrates Deep and Durable Responses - GlobeNewswire
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire Inc.
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - MSN
Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLC - Defense World
PIZZA PIZZA ROYALTY CORP. ANNOUNCES MAY DIVIDEND and TIMING OF ANNUAL GENERAL MEETING - The Globe and Mail
159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust Corp - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company - Defense World
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO - Investing.com Australia
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO By Investing.com - Investing.com Canada
112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG - Defense World
Bicara falls after early-stage trial data for head and neck cancer therapy - MSN
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - MSN
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bicara Therapeutics Inc-Aktie (BCAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Meisner Lara | Chief Legal Officer |
Jun 16 '25 |
Sale |
10.43 |
15,829 |
165,096 |
0 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):